Duration of action of a chimeric interleukin-2 receptor monoclonal antibody, basiliximab, in pediatric kidney transplant recipients

Transplant Proc. 2000 Dec;32(8):2757-9. doi: 10.1016/s0041-1345(00)01868-6.

Authors

G Sterkers¹, V Baudouin, H Ansart-Pirenne, A Maisin, P Niaudet, P Cochat, C Loirat

Affiliation

¹ Laboratoire d'Immunologie Biologique, Hôpital Robert Debré, Paris, France.

PMID: 11134788
DOI: 10.1016/s0041-1345(00)01868-6

No abstract available

Publication types

Clinical Trial
Multicenter Study
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Antibodies, Monoclonal / pharmacokinetics*
Antibodies, Monoclonal / therapeutic use
Basiliximab
Child
Child, Preschool
Humans
Immunosuppressive Agents / pharmacokinetics*
Immunosuppressive Agents / therapeutic use
Infant
Kidney Transplantation / immunology*
Lymphocyte Count
Prospective Studies
Receptors, Interleukin-2 / blood*
Receptors, Interleukin-2 / immunology
Recombinant Fusion Proteins / pharmacokinetics
Recombinant Fusion Proteins / therapeutic use
Time Factors

Substances

Antibodies, Monoclonal
Immunosuppressive Agents
Receptors, Interleukin-2
Recombinant Fusion Proteins
Basiliximab